EH3A Amarin Corporation Plc Sponsored ADR

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET.

The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.  

To enhance engagement with the company’s shareholder base and facilitate connections with its investors, Amarin is partnering with Say Technologies to allow shareholders to submit and upvote questions, a selection of which will be answered by Amarin management during the earnings call. 

Starting on July 17th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: . This Q&A platform will remain open until 24 hours prior to the start of the earnings call. Shareholders can email  for any support inquiries.

Conference Call and Webcast Information: 

 

Access to the live call: 

Go to the investor relations section of the Company's website at  

Dial in within the United States: 888-506-0062

International dial in: 973-528-0011

Access Code: 409616



Access to replay:
 

Dial in within the United States: 877-481-4010 

International dial in: 919-882-2331  

Access Code: 50766



A replay of the call will also be available through the Company's website shortly after the call. 

About Amarin

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.   

Availability of Other Information About Amarin 

Amarin communicates with its investors and the public using the company website () and the investor relations website (), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. 

Amarin Contact Information   

Investor & Media Inquiries:

Mark Marmur

Amarin Corporation plc







EN
17/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amarin Corporation Plc Sponsored ADR

 PRESS RELEASE

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change Action Taken to Maintain Company’s Nasdaq Listing DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company’s previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The objective...

 PRESS RELEASE

Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Direct...

Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. “On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a ...

 PRESS RELEASE

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanist...

Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist – Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Patient Sub-Categories – DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicos...

 PRESS RELEASE

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (...

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March...

 PRESS RELEASE

Amarin Announces Plan to Initiate a Ratio Change Under Its American De...

Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program 1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced its intent to effect a ratio change on its American Depositary Shares (“ADS”) from one (1) ADS representing one (1) ordinary share, to the new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). The effective date of th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch